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Abstract
Hospitalized children < 2 years of age in Amman, Jordan, admitted for fever and/or respiratory 
symptoms, were tested for Middle East respiratory syndrome coronavirus (MERS-CoV): MERS-
CoV by real-time RT-PCR (rRT-PCR). This was a prospective year-round viral surveillance study 
in children <2 years of age admitted with acute respiratory symptoms and/or fever from March 
2010 to September 2012 and enrolled from a government-run hospital, Al-Bashir in Amman, 
Jordan. Clinical and demographic data, including antibiotic use, were collected. Combined nasal/
throat swabs were collected, aliquoted, and frozen at −80°C. Specimen aliquots were shipped to 
Vanderbilt University and the Centers for Disease Control and Prevention (CDC), and tested by 
rRT-PCR for MERS-CoV. Of the 2433 subjects enrolled from 16 March 2010 to 10 September 
2012, 2427 subjects had viral testing and clinical data. Of 1898 specimens prospectively tested for 
other viruses between 16 March 2010 and 18 March 2012, 474 samples did not have other 
common respiratory viruses detected. These samples were tested at CDC for MERS-CoV and all 
were negative by rRT-PCR for MERS-CoV. Of the remaining 531 samples, collected from 19 
March 2012 to 10 September 2012 and tested at Vanderbilt, none were positive for MERS-CoV. 
Our negative findings from a large sample of young Jordanian children hospitalized with fever 
and/or respiratory symptoms suggest that MERS-CoV was not widely circulating in Amman, 
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Jordan, during the 30-month period of prospective, active surveillance occurring before and after 
the first documented MERS-CoV outbreak in the Middle East region.
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Introduction
The recent emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) [1,2], 
first discovered in September 2012, has led to enhanced surveillance efforts throughout the 
world to detect new cases in a timely manner and to better understand the transmission and 
pathogenesis of the virus. Coronaviruses are a diverse group of positive-strand RNA viruses 
that commonly infect the respiratory and gastrointestinal tracts of mammals and birds. 
Human coronaviruses are most commonly associated with mild respiratory illnesses, but can 
cause severe illness, such as severe acute respiratory syndrome (SARS) coronavirus. Genetic 
sequencing data indicate that the MERS-CoV is a betacoronavirus closely related to two bat 
coronaviruses (HKU4 and HKU5), but distinct from other human coronaviruses, including 
SARS-CoV [1,3].
As of November 11, 2013, World Health Organization (WHO) has been informed of a total 
of 151 laboratory-confirmed cases of infection with MERS-CoV, including 64 deaths [4]. 
The cases have originated from the following countries Middle Eastern countries to date: 
Jordan, Qatar, Saudi Arabia and the United Arab Emirates (UAE). France, Germany, Spain, 
Italy, Tunisia and the United Kingdom have also reported laboratory-confirmed cases [2,4, 
5]. The first known MERS-CoV infections were detected retrospectively as occurring in 
April 2012 in Jordan [6]. Based on confirmed cases to date, the clinical syndrome consists of 
febrile illness and pneumonia, as well as renal failure in some patients. The majority of 
reported cases have been in adults and 64 of 151 cases have been fatal (42%) [4]. Some 
cases have occurred in clusters. One cluster involved two cases, both fatal, occurring near 
Amman, Jordan (Zarga, 20 km in distance), in April 2012 [6]. Stored samples from these 
two cases (one hospital worker and one student) tested positive for MERS-CoV 
retrospectively, and this cluster was temporally associated with cases of illness among 
hospital workers. Several other clusters suggested human transmission [5,7,8]; although the 
risk of sustained transmission is unknown [2,5].
The epidemiology of MERS-CoV, including its potential distribution among paediatric cases 
of severe acute respiratory illness (ARI), has not been characterized. A critical question is 
whether the cases identified thus far are the only MERS-CoV infections or whether the virus 
has circulated more widely undetected. This is of interest in light of the epidemiology of 
SARS-CoV, where infections in children < 12 years of age were generally milder, with no 
mortality and few hospitalizations [9]. To determine whether MERS-CoV was present 
among young paediatric ARI cases before, during and after the occurrence of the Zarga, 
Jordan MERS-CoV cluster, we tested upper respiratory tract specimens collected from a 
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prospective study of paediatric ARI hospitalizations in Amman, Jordan, from March 2010 to 
September 2012.
Methods
Study design
A prospective year-round viral surveillance study in children <2 years admitted with 
respiratory symptoms and/or fever commenced on 16 March 2010 at Al Basheer Hospital, 
the main government-run hospital and referral centre in Amman, Jordan, with 240 paediatric 
hospital beds and catchment of approximately one million persons (50% of the population). 
Subjects were enrolled 5 days per week (Sunday–Thursday) for approximately 30 months 
from March 2010 to September 2012. After consent was obtained, the child’s clinical 
symptoms before admission to the hospital and demographic information were collected by 
parental interview. Medical records were reviewed to determine the hospital course and 
clinical outcomes. Institutional Review Board approval was obtained from Vanderbilt 
University, Jordan University and the Jordanian Ministry of Health.
Specimen collection
Nasal and throat swabs were collected and combined in transport medium (M4RT®, Remel, 
Lenexa, KS, USA), aliquoted into MagMAX™ Lysis/Binding Solution Concentrate (Life 
Technologies, Grand Island, NY, USA), snap frozen, and stored at −80°C. Original and lysis 
buffer aliquots were shipped to Vanderbilt University on dry ice for testing by real-time RT-
PCR (rRT-PCR) for respiratory syncytial virus, human metapneumovirus, rhinovirus, 
influenza A and B, and parainfluenza virus one, two and three [10]. Samples tested by 
Vanderbilt that had no viruses detected were sent to the CDC for MERS-CoV testing and 
samples not previously tested for any respiratory viruses were tested for MERS-CoV at 
Vanderbilt.
Laboratory methods
At Vanderbilt. PCR testing—Nucleic acid extraction and real-time RT-PCR 
(rRT-PCR) testing—RNA was extracted from thawed specimens according to the 
manufacturer’s protocols for the MagMAX-96™ Viral RNA Isolation Kit (Life 
Technologies). Primers and probes were synthesized by a commercial supplier (Eurofins 
MWG Operon, Huntsville, AL, USA) based on previously described sequences [11]. rRT-
PCR assays were designed to target the upE and ORF1b regions of the MERS-CoV genome. 
As a positive control, the target sequence of the upE assay and flanking nucleotides (c. 400 
bp total) were synthesized by a commercial source (Genscript, Piscataway, NJ, USA) and 
cloned into plasmid pUC57. One-step rRT-PCR reactions were prepared using the AgPath-
ID One-Step RT-PCR kit (Life Technologies) according to the manufacturer’s instructions 
with 400 nM forward and reverse primers and 200 nM probe. Cycling parameters were 50°C 
× 30 min, 95°C × 10 min and 45 cycles of 95°C × 15 s and 58°C × 30 s, with fluorescence 
data collected during the 60°C annealing/extension step. Specimens were tested first by the 
upE assay using 5 μL of RNA. Potential positives were then retested using the ORF1b assay 
and the upE assay was repeated, both with 10 μL of RNA.
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Culture—Cells and viruses—Vero and LLC-MK2 cells were maintained in OptiMEM® 
(Life Technologies) media supplemented with 2% fetal calf serum, gentamicin, 
amphotericin B, glutamine and tylosin. All virus work was performed in a biosafety level 
(BSL) three laboratory following IBC-approved BSL-3 procedures.
Virus recovery—Vero and LLC-MK2 cells were plated in 25-cm2 flasks. The next day, 
media was removed and then 1 ml was added back. Frozen specimen aliquots were thawed 
on ice and 75–100 μL of specimen or PBS (mock) were added to the flasks. Flasks were 
maintained at 37°C, 5% CO2 for 30 min, with rocking every 10 min, and then 2 mL of Opti-
MEM was added to each flask and flasks were returned to the incubator. Flasks were 
examined for cytopathic effect (CPE) every 24–48 h.
At CDC. PCR testing—Briefly, total nucleic acids (TNAs) were extracted from 200 μL of 
the swab specimens using the NucliSENS® easyMAG® (bioMérieux, Durham, NC, USA). 
All specimens were tested by three discrete rRT-PCR assays: the upE assay as described 
above and two in-house developed assays targeting the MERS-CoV nucleocapsid gene. All 
assays were performed in 25 μL final reaction volumes containing 5 μL of sample TNA 
extract using the Invitrogen SuperScript® III Platinum® One-Step Quantitative RT-PCR 
System (Life Technologies) on an Applied Biosystems® 7500 Fast Dx Real-Time PCR 
instrument (Life Technologies). Positive test results were assigned to samples generating 
well-defined fluorescent curves that crossed the threshold within 45 cycles for any assay and 
were further investigated. Positive (MERS-CoV RNA transcript template) and negative 
(nuclease-free water) controls were included in all runs to monitor assay performance. All 
samples were also tested by rRT-PCR for the presence of the human ribonuclease P gene as 
a control for specimen quality.
Results
Of the 2433 subjects enrolled from 16 March 2010 to 10 September 2012, 2427 specimens 
were available for PCR testing for MERS-CoV and had clinical data available. The median 
age was 3.5 months, 60% were male, and 10% had an underlying medical condition, 30% 
required oxygen, 11% had the diagnosis of pneumonia and 7% were admitted to the ICU. In 
addition, 2% attended day care and 76% were exposed to smokers. The majority (97%) of 
the fathers were employed, and 39.6%, 44.8% and 10% of the mothers finished primary 
education, secondary education and college, respectively. The majority of children lived in 
Amman; however, some children lived in the surrounding cities, including Zarqa (34 
children, 1.4%). Table 1 includes demographic data, diagnoses and outcome data for the 
entire group and by testing sites.
Of 1898 specimens prospectively tested for other viruses during 2-year surveillance period 
between 16 March 2010 and 18 March 2012, 474 samples did not have other common 
respiratory viruses detected. These samples were tested at CDC for MERS-CoV and none 
were found to be positive by rRT-PCR for MERS-CoV. The remaining 531 samples 
collected from 19 March 2012 to 10 September 2012 were tested at Vanderbilt using the 
MERS-CoV upE assay with 5 μL of RNA extract per reaction. Four of the samples gave 
positive reactions with high cycle threshold (Ct) values (c. 38). These specimens were 
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retested using the upE and Orf1b rRT-PCR assays with 10 μL of RNA per reaction and all 
were negative. Finally, these specimens were retested using the CDC MERS-CoV 
nucleocapsid primers and probes provided to Vanderbilt and were also negative. These four 
specimens were then inoculated into Vero and LLC-MK2 cells. Three of the samples 
showed evidence of bacterial or fungal contamination within 24–48 h following inoculation 
and were discarded and not recultured due to lack of an adequate amount of samples. Cells 
inoculated with the fourth sample were monitored for 7 days and then passaged into new 
cultures and followed for an additional 10 days. No CPE was detected.
Comparisons among the three groups were made using the Kruskal–Wallis test or Pearson 
chi-square test for continuous variables and categorical variables, respectively.
Discussion
Despite the close proximity of the first documented MERS-CoV outbreak in Zarga in April 
2012, we did not detect MERS-CoV among children < 2 years of age who were hospitalized 
with ARI during that same time period in Amman, Jordan, just 20 km away. Young children 
are known to be a source of respiratory viral transmission; therefore, our negative findings 
epidemiologically suggest that MERS-CoV may not have been widely circulating in nearby 
metropolitan Amman, Jordan, during this interval. This is an important finding because there 
remains uncertainty over whether confirmed MERS-CoV cases are more likely to be 
detected due to the severity of illness, and the full extent to which MERS-CoV circulates 
more widely causing mild illness [8]. Nevertheless, further surveillance is still needed in the 
Arabian Peninsula and neighbouring countries to monitor current circulation and possible 
emergence of widespread transmission. The majority of the MERS-CoV cases reported to 
date have been in adults and the common symptoms have included fever, cough and 
shortness of breath, with a high proportion of cases resulting in death [1,2,5,6,8].
Four specimens tested preliminarily positive for MERS-CoV by the upE rRT-PCR assay, 
albeit with high Ct values; however, further testing confirmed that these were false-positive 
results. This illustrates that with any assay, even in an experienced laboratory, false positives 
can occur. Thus, given the public health importance of this virus, further confirmatory 
testing should be performed on all provisionally test-positive specimens.
Our study is limited by the fact that only hospitalized children with ARI were enrolled, and 
thus we may have missed milder cases of MERS-CoV infection among outpatient children. 
For example, children < 12 years of age infected with SARS-CoV were reported to have 
milder disease compared with older children and adults [9,12,13]. Nose/throat swabs 
obtained during acute respiratory disease were tested, and the sensitivity of this specimen 
type for detecting MERS-CoV is currently unknown. The CDC recommends collecting 
respiratory specimens from different sites and at different stages of the illness, with lower 
respiratory tract specimens prioritized, but existing routine surveillance in the Middle East 
and elsewhere typically focuses on nose/throat swabs [5,14]. Only samples that tested 
negative for a virus were sent to the CDC for testing; therefore, we may have missed 
instances of MERS-CoV co-infections, but all respiratory samples collected after the first 
MERS-CoV cluster occured in Jordan in April 2012 were tested. However, a strength of our 
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study is that we tested almost 1000 children hospitalized with ARI symptoms for MERS-
CoV. Of note, another study described lack of detecting MERS-CoV from nasal swabs from 
a group of French Hajj pilgrims after returning to France, despite a high rate of respiratory 
symptoms [15].
In conclusion, our negative findings suggest that MERS-CoV has not widely circulated in 
Amman, Jordan, during the 30-month period of prospective, active surveillance occurring 
before and after the first documented outbreak of MERS-CoV in the region. Our study 
confirms the value of prospective viral surveillance infrastructure to facilitate rapid 
responses to emerging pathogens.
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